Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (589) 589
science & technology (506) 506
life sciences & biomedicine (499) 499
male (328) 328
female (302) 302
pharmacology & pharmacy (267) 267
azabicyclo compounds - therapeutic use (262) 262
piperazines - therapeutic use (262) 262
hypnotics and sedatives - therapeutic use (236) 236
azabicyclo compounds (232) 232
middle aged (230) 230
adult (224) 224
sleep initiation and maintenance disorders - drug therapy (181) 181
animals (165) 165
azabicyclo compounds - pharmacology (165) 165
biological and medical sciences (161) 161
medical sciences (155) 155
aged (149) 149
piperazines - adverse effects (144) 144
hypnotics and sedatives - adverse effects (133) 133
double-blind method (126) 126
pharmacology. drug treatments (115) 115
neurosciences & neurology (111) 111
microbiology (103) 103
azabicyclo compounds - adverse effects (102) 102
insomnia (97) 97
ceftazidime - therapeutic use (95) 95
anti-bacterial agents - therapeutic use (93) 93
zopiclone (89) 89
neurosciences (88) 88
psychiatry (87) 87
microbial sensitivity tests (84) 84
azabicyclo compounds - administration & dosage (83) 83
treatment outcome (80) 80
pyridines - therapeutic use (79) 79
eszopiclone (76) 76
clinical neurology (72) 72
mice (70) 70
psychology. psychoanalysis. psychiatry (70) 70
infectious diseases (63) 63
neuropharmacology (63) 63
anti-bacterial agents - pharmacology (61) 61
drug combinations (61) 61
piperazines - administration & dosage (61) 61
psychopharmacology (60) 60
young adult (60) 60
piperazines - pharmacology (59) 59
adolescent (58) 58
drug therapy (55) 55
dose-response relationship, drug (54) 54
hypnotics and sedatives - administration & dosage (53) 53
sleep - drug effects (53) 53
benzodiazepines (50) 50
rats (50) 50
azabicyclo compounds - pharmacokinetics (48) 48
ceftazidime - pharmacology (47) 47
azabicyclo compounds - chemistry (46) 46
hypnotics and sedatives - pharmacology (46) 46
neurology (46) 46
pyridines - adverse effects (46) 46
beta-lactamase inhibitors - therapeutic use (45) 45
hypnotics (45) 45
pyrimidines - therapeutic use (45) 45
zolpidem (44) 44
clinical trials as topic (43) 43
aged, 80 and over (42) 42
care and treatment (41) 41
benzodiazepines - therapeutic use (40) 40
beta-lactamases - metabolism (40) 40
ceftazidime (40) 40
acetamides - therapeutic use (39) 39
time factors (39) 39
hypnotics. sedatives (38) 38
klebsiella pneumoniae - drug effects (36) 36
pharmacology (36) 36
pharmacology/toxicology (36) 36
research (36) 36
sleep (36) 36
analysis (35) 35
chronic disease (35) 35
drug therapy, combination (35) 35
abridged index medicus (34) 34
beta-lactamase inhibitors - pharmacology (34) 34
general & internal medicine (34) 34
gram-negative bacteria - drug effects (33) 33
medicine & public health (33) 33
drug resistance, multiple, bacterial (32) 32
medicine, general & internal (32) 32
nervous system (32) 32
drugs (31) 31
enterobacteriaceae - drug effects (31) 31
gram-negative bacterial infections - drug therapy (31) 31
pseudomonas aeruginosa - drug effects (31) 31
clinical trials (30) 30
cross-over studies (30) 30
oncology (30) 30
health aspects (29) 29
toxicology (29) 29
beta-lactamases - genetics (28) 28
polycyclic compounds (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (667) 667
German (17) 17
Russian (11) 11
French (5) 5
Japanese (3) 3
Spanish (3) 3
Dutch (2) 2
Finnish (2) 2
Portuguese (2) 2
Chinese (1) 1
Danish (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Diversity-oriented synthesis yields novel multistage antimalarial inhibitors
by Kato, Nobutaka and Comer, Eamon and Sakata-Kato, Tomoyo and Sharma, Arvind and Sharma, Manmohan and Maetani, Micah and Bastien, Jessica and Brancucci, Nicolas M and Bittker, Joshua A and Corey, Victoria and Clarke, David and Derbyshire, Emily R and Dornan, Gillian L and Duffy, Sandra and Eckley, Sean and Itoe, Maurice A and Koolen, Karin M. J and Lewis, Timothy A and Lui, Ping S and Lukens, Amanda K and Lund, Emily and March, Sandra and Meibalan, Elamaran and Meier, Bennett C and McPhail, Jacob A and Mitasev, Branko and Moss, Eli L and Sayes, Morgane and Van Gessel, Yvonne and Wawer, Mathias J and Yoshinaga, Takashi and Zeeman, Anne-Marie and Avery, Vicky M and Bhatia, Sangeeta N and Burke, John E and Catteruccia, Flaminia and Clardy, Jon C and Clemons, Paul A and Dechering, Koen J and Duvall, Jeremy R and Foley, Michael A and Gusovsky, Fabian and Kocken, Clemens H. M and Marti, Matthias and Morningstar, Marshall L and Munoz, Benito and Neafsey, Daniel E and Sharma, Amit and Winzeler, Elizabeth A and Wirth, Dyann F and Scherer, Christina A and Schreiber, Stuart L
Nature (London), ISSN 0028-0836, 2016, Volume 538, Issue 7625, pp. 344 - 349
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Azabicyclo Compounds - pharmacology | Plasmodium falciparum - enzymology | Malaria, Falciparum - prevention & control | Male | Plasmodium falciparum - cytology | Azetidines - pharmacology | Plasmodium falciparum - drug effects | Cytosol - enzymology | Malaria, Falciparum - transmission | Liver - drug effects | Azabicyclo Compounds - chemical synthesis | Azabicyclo Compounds - therapeutic use | Female | Safety | Antimalarials - chemical synthesis | Disease Models, Animal | Life Cycle Stages - drug effects | Malaria, Falciparum - drug therapy | Azabicyclo Compounds - administration & dosage | Azetidines - adverse effects | Phenylurea Compounds - therapeutic use | Antimalarials - therapeutic use | Macaca mulatta - parasitology | Phenylalanine-tRNA Ligase - antagonists & inhibitors | Drug Discovery | Antimalarials - pharmacology | Animals | Azetidines - administration & dosage | Phenylurea Compounds - chemical synthesis | Antimalarials - administration & dosage | Azetidines - therapeutic use | Phenylurea Compounds - administration & dosage | Mice | Phenylurea Compounds - pharmacology | Liver - parasitology | Plasmodium falciparum - growth & development | Prevention | Antimalarials | Disease transmission | Health aspects | Transfer RNA | Proteins | Cytochrome | Malaria | Liver | Parasites | Kinases | Drug resistance | Drug dosages | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text New β-lactamase inhibitors: A therapeutic renaissance in an MDR world
by Drawz, Sarah M and Papp-Wallace, Krisztina M and Bonomo, Robert A
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 2014, Volume 58, Issue 4, pp. 1835 - 1846
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Azabicyclo Compounds - pharmacology | Humans | Enzyme Inhibitors - pharmacology | Gram-Negative Bacterial Infections - drug therapy | Enzyme Inhibitors - therapeutic use | Gram-Negative Bacteria - enzymology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Gram-Negative Bacteria - drug effects | Drug Resistance, Multiple, Bacterial | Azabicyclo Compounds - therapeutic use | Anti-Bacterial Agents - pharmacology | beta-Lactamase Inhibitors | Index Medicus | Minireview
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Model-based Drug Development
by Lalonde, R L and Kowalski, K G and Hutmacher, M M and Ewy, W and Nichols, D J and Milligan, P A and Corrigan, B W and Lockwood, P A and Marshall, S A and Benincosa, L J and Tensfeldt, T G and Parivar, K and Amantea, M and Glue, P and Koide, H and Miller, R
Clinical pharmacology and therapeutics, ISSN 0009-9236, 07/2007, Volume 82, Issue 1, pp. 21 - 32
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Pharmacology. Drug treatments | Medical sciences | Analgesics - pharmacology | Muscarinic Agonists - pharmacology | Cholesterol - blood | Humans | Glycoproteins - pharmacology | Caproates - therapeutic use | Amines - therapeutic use | Alzheimer Disease - psychology | Neutrophil Infiltration - drug effects | United States Food and Drug Administration | Glycoproteins - therapeutic use | Alzheimer Disease - drug therapy | gamma-Aminobutyric Acid - pharmacology | Stroke - drug therapy | Cognition - drug effects | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Models, Biological | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Amines - pharmacology | Immunologic Factors - pharmacology | Clinical Trials as Topic - legislation & jurisprudence | Guidelines as Topic | Meta-Analysis as Topic | Clinical Trials as Topic - statistics & numerical data | United States | Caproates - pharmacology | Muscarinic Agonists - therapeutic use | Oximes - therapeutic use | Drug Approval | Hypercholesterolemia - drug therapy | Dose-Response Relationship, Drug | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Computer Simulation | Drug Design | gamma-Aminobutyric Acid - therapeutic use | Stroke - immunology | Analgesics - therapeutic use | Cyclohexanecarboxylic Acids - therapeutic use | Hypercholesterolemia - blood | Reproducibility of Results | Neuralgia, Postherpetic - drug therapy | Pharmacology | Models, Statistical | Animals | Anticholesteremic Agents - therapeutic use | Cyclohexanecarboxylic Acids - pharmacology | Oximes - pharmacology | Clinical Trials as Topic - methods | Pharmacokinetics | Research Design | Anticholesteremic Agents - pharmacology | Immunologic Factors - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
by Pogue, Jason M and Bonomo, Robert A and Kaye, Keith S
Clinical infectious diseases, ISSN 1058-4838, 01/2019, Volume 68, Issue 3, pp. 519 - 524
carbapenem-resistant Enterobacteriaceae | ceftazidime/avibactam | Klebsiella pneumoniae carbapenemase | meropenem/vaborbactam | antimicrobial stewardship | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Carbapenem-Resistant Enterobacteriaceae - isolation & purification | Enterobacteriaceae Infections - microbiology | Humans | Boronic Acids - therapeutic use | Meropenem - therapeutic use | Anti-Bacterial Agents - therapeutic use | beta-Lactamase Inhibitors - therapeutic use | Heterocyclic Compounds, 1-Ring - therapeutic use | Azabicyclo Compounds - therapeutic use | Disease Management | Carbapenem-Resistant Enterobacteriaceae - drug effects | Ceftazidime - therapeutic use | Drug Combinations | Enterobacteriaceae Infections - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program
by Mazuski, John E and Gasink, Leanne B and Armstrong, Jon and Broadhurst, Helen and Stone, Greg G and Rank, Douglas and Llorens, Lily and Newell, Paul and Pachl, Jan
Clinical infectious diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 11, pp. 1380 - 1389
phase 3 | complicated intra-abdominal infection | meropenem | ceftazidime-avibactam plus metronidazole | noninferiority | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Middle Aged | Male | Young Adult | Anti-Bacterial Agents - therapeutic use | Metronidazole - therapeutic use | Aged, 80 and over | Metronidazole - adverse effects | Adult | Azabicyclo Compounds - therapeutic use | Female | Anti-Bacterial Agents - adverse effects | Thienamycins - adverse effects | Azabicyclo Compounds - adverse effects | Thienamycins - therapeutic use | Thienamycins - administration & dosage | Azabicyclo Compounds - administration & dosage | Metronidazole - administration & dosage | Treatment Outcome | Intraabdominal Infections - epidemiology | Adolescent | Ceftazidime - administration & dosage | Aged | Ceftazidime - adverse effects | Anti-Bacterial Agents - administration & dosage | Intraabdominal Infections - drug therapy | Ceftazidime - therapeutic use | Usage | Care and treatment | Abscess | Clinical trials | Dosage and administration | Ceftazidime | Abdomen | Confidence intervals | Prescription drugs | Pathogens | Antibiotics | Index Medicus | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection
by Lucasti, Christopher and Vasile, Liviu and Sandesc, Dorel and Venskutonis, Donatas and McLeroth, Patrick and Lala, Mallika and Rizk, Matthew L and Brown, Michelle L and Losada, Maria C and Pedley, Alison and Kartsonis, Nicholas A and Paschke, Amanda
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 10/2016, Volume 60, Issue 10, pp. 6234 - 6243
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Imipenem - therapeutic use | Humans | Middle Aged | Cilastatin - pharmacokinetics | Male | Imipenem - pharmacokinetics | Young Adult | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Adult | Azabicyclo Compounds - therapeutic use | Female | Anti-Bacterial Agents - adverse effects | Cilastatin - therapeutic use | Azabicyclo Compounds - pharmacokinetics | Drug Therapy, Combination | Bacterial Infections - microbiology | Azabicyclo Compounds - adverse effects | Double-Blind Method | Bacterial Infections - drug therapy | Intraabdominal Infections - microbiology | Azabicyclo Compounds - administration & dosage | Treatment Outcome | Adolescent | Anti-Bacterial Agents - pharmacokinetics | Aged | Anti-Bacterial Agents - administration & dosage | Intraabdominal Infections - drug therapy | Drug Combinations | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
by Wagenlehner, Florian M and Sobel, Jack D and Newell, Paul and Armstrong, Jon and Huang, Xiangning and Stone, Gregory G and Yates, Katrina and Gasink, Leanne B
Clinical infectious diseases, ISSN 1058-4838, 09/2016, Volume 63, Issue 6, pp. 754 - 762
acute pyelonephritis | ceftazidime-avibactam | complicated urinary tract infection | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Doripenem | Azabicyclo Compounds - administration & dosage | Carbapenems - administration & dosage | Humans | Middle Aged | Male | Pyelonephritis - complications | Urinary Tract Infections - complications | Urinary Tract Infections - drug therapy | Carbapenems - adverse effects | Anti-Bacterial Agents - therapeutic use | Carbapenems - therapeutic use | Ceftazidime - administration & dosage | Adult | Azabicyclo Compounds - therapeutic use | Female | Aged | Anti-Bacterial Agents - adverse effects | Ceftazidime - adverse effects | Pyelonephritis - drug therapy | Anti-Bacterial Agents - administration & dosage | Ceftazidime - therapeutic use | Drug Combinations | Azabicyclo Compounds - adverse effects | Care and treatment | Usage | Pyelonephritis | Clinical trials | Urinary tract infections | Influence | Dosage and administration | Ceftazidime | Antibiotics | Drug resistance | Drug therapy | CRE bacteria | Urinary tract diseases | Index Medicus | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Pharmacological interventions for sleepiness and sleep disturbances caused by shift work
by Liira, Juha and Verbeek, Jos H and Costa, Giovanni and Driscoll, Tim R and Sallinen, Mikael and Isotalo, Leena K and Ruotsalainen, Jani H and Liira, Juha
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 8, pp. CD009776 - CD009776
Wakefulness‐Promoting Agents | Melatonin | Piperazines | Benzhydryl Compounds | Mental health | 2. Management of occupational disease or symptoms | 1.1.3 Circadian rhythm disruption (e.g. shiftwork) | Randomized Controlled Trials as Topic | Sleep | Modafinil | Wakefulness | Sleep Disorders, Circadian Rhythm | Azabicyclo Compounds | Hypnotics and Sedatives | Managing occupational disease | Occupational health outcome | 1.1 Decreasing or eliminating harmful exposure to prevent occupational disease | Medicine General & Introductory Medical Sciences | 2.1.2 Mental and behavioural disorders | Caffeine | Health & safety at work | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Wakefulness-Promoting Agents - therapeutic use | Wakefulness - drug effects | Humans | Piperazines - therapeutic use | Hypnotics and Sedatives - therapeutic use | Sleep - drug effects | Sleep Disorders, Circadian Rhythm - drug therapy | Caffeine - therapeutic use | Melatonin - therapeutic use | Wakefulness - physiology | Azabicyclo Compounds - therapeutic use | Sleep - physiology | Benzhydryl Compounds - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights